title: Peroxisome proliferator-activated receptor-gamma-mediated effects in the vasculature.
abstract: Peroxisome proliferator-activated receptor (PPAR)-gamma is a nuclear receptor and transcription factor in the steroid superfamily. PPAR-gamma agonists, the thiazolidinediones, are clinically used to treat type 2 diabetes. In addition to its function in adipogenesis and increasing insulin sensitivity, PPAR-gamma also plays critical roles in the vasculature. In vascular endothelial cells, PPAR-gamma activation inhibits endothelial inflammation by suppressing inflammatory gene expression and therefore improves endothelial dysfunction. In vascular smooth muscle cells, PPAR-gamma activation inhibits proliferation and migration and promotes apoptosis. In macrophages, PPAR-gamma activation suppresses inflammation by regulating gene expression and increases cholesterol uptake and efflux. A recurring theme in many cell types is the modulation of the innate immunity system particularly through altering the activity of the nuclear factor kappaB. This system is likely to be even more prominent in modulating disease in vascular cells. The effects of PPAR-gamma in the vascular cells translate into the beneficial function of this transcription factor in vascular disorders, including hypertension and atherosclerosis. Both human genetic studies and animal studies using transgenic mice have demonstrated the importance of PPAR-gamma in these disorders. However, recent clinical studies have raised significant concerns about the cardiovascular side effects of thiazolidinediones, particularly rosiglitazone. Weighing the potential benefit and harm of PPAR-gamma activation and exploring the functional mechanisms may provide a balanced view on the clinical use of these compounds and new approaches to the future therapeutics of vascular disorders associated with diabetes.
authors.affiliation: Department of Molecular and Integrative Physiology, University of Michigan Medical School, Ann Arbor, MI 48109-0622, USA.
authors.forename: Sheng Zhong
authors.initials: SZ
authors.lastname: Duan
authors.forename: Michael G
authors.initials: MG
authors.lastname: Usher
authors.forename: Richard M
authors.initials: RM
authors.lastname: Mortensen
mesh_terms: D050156:Adipogenesis / Q000187:drug effects / Q000276:immunology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects / Q000276:immunology; D050197:Atherosclerosis / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D002465:Cell Movement / Q000187:drug effects / Q000276:immunology; D049109:Cell Proliferation / Q000187:drug effects; D002784:Cholesterol / Q000276:immunology / Q000378:metabolism; D048909:Diabetes Complications / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism; D042783:Endothelial Cells / Q000276:immunology / Q000378:metabolism*; D005786:Gene Expression Regulation / Q000187:drug effects / Q000276:immunology; D006801:Humans; D006973:Hypertension / Q000276:immunology / Q000378:metabolism; D007113:Immunity, Innate / Q000187:drug effects / Q000276:immunology; D007249:Inflammation / Q000188:drug therapy / Q000276:immunology / Q000378:metabolism; D007328:Insulin / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008822:Mice, Transgenic; D032389:Myocytes, Smooth Muscle / Q000276:immunology / Q000378:metabolism*; D016328:NF-kappa B / Q000276:immunology / Q000378:metabolism; D047495:PPAR gamma / Q000819:agonists / Q000276:immunology / Q000378:metabolism*; D045162:Thiazolidinediones / Q000627:therapeutic use
chemical_list: D007328:Insulin; D016328:NF-kappa B; D047495:PPAR gamma; D045162:Thiazolidinediones; D002784:Cholesterol